.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 8,200,327

« Back to Dashboard

Details for Patent: 8,200,327

Title:Device for transdermal electrotransport delivery of fentanyl and sufentanil
Abstract: The invention provides an improved electrotransport drug delivery system for analgesic drugs, namely fentanyl and sufentanil. The fentanyl/sufentanil is provided as a water soluble salt (e.g., fentanyl hydrochloride), preferably in a hydrogel formulation, for use in an electrotransport device. In accordance with the present invention, a transdermal electrotransport delivered dose of fentanyl/sufentanil is provided which is sufficient to induce analgesia in (e.g., adult) human patients suffering from moderate-to-severe pain associated with major surgical procedures.
Inventor(s): Southam; Mary (Menlo Park, CA), Bernstein; Keith J. (Somerville, NJ), Noorduin; Henk (Bergen op Zoom, NL)
Assignee: ALZA Corporation (Vacaville, CA)
Filing Date:Jul 12, 2006
Application Number:11/456,952
Claims:1. A patient-worn device for transdermally delivering fentanyl solely by electrically induced or electrically enhanced electrotransport to a human patient suffering from pain, comprising: a donor reservoir formulation comprised of a fentanyl salt solution being the sole source of fentanyl in the device; a counter reservoir; a source of electrical power electrically connected to said reservoirs; and a control circuit for controlling electrotransport current, said control circuit including a switch which activates said device and wherein said reservoirs, said power source and said control circuit deliver solely by electrotransport a dose of about 20 .mu.g to about 60 .mu.g of fentanyl over a predetermined delivery period of up to about 20 minutes and terminate said delivery at the end of said delivery period, and wherein said control circuit allows up to 143 additional of said doses over a period of about 24 hours.

2. The device of claim 1, wherein said control circuit allows up to about 10-100 additional of the doses is delivered over a period of about 24 hours.

3. The device of claim 2, wherein said control circuit allows up to about 20-80 additional of the doses is delivered over a period of about 24 hours.

4. A patient-worn device for transdermally delivering sufentanil solely by electrically induced or electrically enhanced electrotransport to a human patient suffering from pain, comprising: a donor reservoir formulation comprised of a sufentanil salt solution being the sole source of sufentanil in the device; a counter reservoir; a source of electrical power electrically connected to said reservoirs; and a control circuit for controlling electrotransport current, said control circuit including a switch which activates said device, wherein said donor reservoir, said power source and said control circuit deliver solely by electrotransport a dose of about 2.3 .mu.g to about 7.0 .mu.g of sufentanil over a predetermined delivery period of up to about 20 minutes and terminate said delivery at the end of said delivery period, and wherein said control circuit allows up to 143 additional of said doses over a period of about 24 hours.

5. The device of claim 4, wherein said control circuit allows up to about 10-100 additional of the doses is delivered over a period of about 24 hours.

6. The device of claim 5, wherein said control circuit allows up to about 20-80 additional of the doses is delivered over a period of about 24 hours.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc